Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Humacyte (HUMA) Change in Account Payables (2024 - 2025)

Humacyte has reported Change in Account Payables over the past 2 years, most recently at -$4.2 million for Q4 2025.

Quarterly results put Change in Account Payables at -$4.2 million for Q4 2025, down 70.74% from a year ago — trailing twelve months through Dec 2025 was $973000.0 (up 149.59% YoY), and the annual figure for FY2025 was $973000.0, up 149.59%.
Change in Account Payables for Q4 2025 was -$4.2 million at Humacyte, down from $3.0 million in the prior quarter.
Over the last five years, Change in Account Payables for HUMA hit a ceiling of $3.0 million in Q3 2025 and a floor of -$4.2 million in Q4 2025.